Public Market Listing
Live quotes, historical charts, and market capitalization for Zealand Pharma are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(6 total)
| Target & Modality | |||
|---|---|---|---|
dasiglucagon(Zegalogue) | Approved | Glucagon receptor (agonist)Peptide | Diabetes / Hypoglycemia Severe Hypoglycemia |
lixisenatide(Adlyxin / Lyxumia) | Approved | GLP-1 receptorPeptide | Type 2 Diabetes |
| Phase 3 | Amylin receptor · Amylin/calcitonin receptor (dual)Peptide | Obesity | |
| Phase 3 | GLP-1/glucagon receptor (dual)Peptide | ObesityType 2 DiabetesMASH / NASH | |
| Phase 2 | GLP-1/GLP-2 receptor (dual)Peptide | Obesity | |
| Phase 1 | GIP receptorPeptide | Obesity |
Discontinued programmes (1)
Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.
Upcoming events
(10 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
November 2027 (1)
What to watch
2028 (4)
2029 (3)
2030 (1)
July 2030 (1)
What to watch
2031 (1)
December 2031 (1)
What to watch
Regulatory and conference events
(4)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (2)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q1 | $5.3M | — | $2.2B | — | report ↗ |
View 1 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-H1 | $1.3B | — | $2.6B | — | report ↗ |
Annual history (3 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $1.4B | — | $2.4B | — | report ↗ |
For FY 2025, Zealand Pharma reported revenue of $1,393.89M, up 15,234.3% YoY, with R&D spend not disclosed and cash and equivalents of $2,378.16M. Net income/loss and quarterly net burn were not disclosed, though the company reported an operating result of DKK 6,959M.
The company guided 2026 net operating expenses (excl. OOI) to DKK 2,700–3,300M and noted eligibility for potential Roche milestones of USD 700M, including USD 575M tied to Phase 3a initiation and USD 125M in Q2 2026. Key events included the Roche collaboration for petrelintide, expected Phase 2 ZUPREME-1 topline data in Q1 2026, Phase 3 survodutide data expected during 2026, dasiglucagon NDA resubmission planned for H2 2026, glepaglutide Phase 3 EASE-5 recruitment and EU MAA submission, positive Phase 1a SAD data for ZP9830, and plans for a Boston research site and a first-in-human trial for ZP6590 in 2026.